• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Keros Therapeutics Inc.

    2/17/26 4:15:06 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KROS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Keros Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)


    492327101

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    TANG CAPITAL MANAGEMENT, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    KEVIN TANG
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS INTERNATIONAL, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS III, INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    492327101


    1Names of Reporting Persons

    TANG CAPITAL PARTNERS IV, INC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Keros Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    1050 Waltham Street, Suite 302, Lexington, MA, 02421
    Item 2. 
    (a)Name of person filing:

    This Statement on Schedule 13G (this "Statement") is filed by Tang Capital Management, LLC ("TCM"), the general partner of Tang Capital Partners, LP ("TCP") and Tang Capital Partners International, LP ("TCPI"); Kevin Tang, the manager of TCM and Chief Executive Officer of Tang Capital Partners III, Inc. ("TCP III") and Tang Capital Partners IV, Inc. ("TCP IV"); TCP; TCPI; TCP III; and TCP IV.
    (b)Address or principal business office or, if none, residence:

    The address of TCM, Kevin Tang, TCP and TCPI is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101.
    (c)Citizenship:

    TCM is a Delaware limited liability company. Mr. Tang is a United States citizen. TCP and TCPI are Delaware limited partnerships. TCP III and TCP IV are Nevada corporations that are indirectly wholly owned by TCP.
    (d)Title of class of securities:

    Common Stock, par value $0.0001 per share
    (e)CUSIP No.:

    492327101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0 shares

     (ii) Shared power to vote or to direct the vote:

    0 shares

     (iii) Sole power to dispose or to direct the disposition of:

    0 shares

     (iv) Shared power to dispose or to direct the disposition of:

    0 shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    TANG CAPITAL MANAGEMENT, LLC
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager
    Date:02/17/2026
     
    KEVIN TANG
     
    Signature:/s/ Kevin Tang
    Name/Title:Self
    Date:02/17/2026
     
    TANG CAPITAL PARTNERS, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:02/17/2026
     
    TANG CAPITAL PARTNERS INTERNATIONAL, LP
     
    Signature:/s/ Kevin Tang
    Name/Title:Manager, Tang Capital Management, LLC, General Partner
    Date:02/17/2026
     
    TANG CAPITAL PARTNERS III, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:02/17/2026
     
    TANG CAPITAL PARTNERS IV, INC
     
    Signature:/s/ Kevin Tang
    Name/Title:Chief Executive Officer
    Date:02/17/2026
    Get the next $KROS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KROS

    DatePrice TargetRatingAnalyst
    10/20/2025$26.00Overweight
    Wells Fargo
    6/10/2025$18.00Buy → Neutral
    BofA Securities
    1/21/2025Overweight → Neutral
    Cantor Fitzgerald
    1/17/2025$15.00Outperform → Neutral
    Wedbush
    12/16/2024$102.00 → $63.00Outperform
    Oppenheimer
    12/16/2024Buy → Neutral
    Guggenheim
    12/13/2024$100.00 → $47.00Buy
    H.C. Wainwright
    12/12/2024Buy → Hold
    TD Cowen
    More analyst ratings

    $KROS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Keros Therapeutics Inc.

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    3/11/26 4:39:18 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Keros Therapeutics Inc.

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    3/11/26 4:33:59 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by Keros Therapeutics Inc.

    3 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    3/11/26 4:37:23 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS

    LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it has entered into an agreement with the Massachusetts General Hospital ("MGH") for the design of a Phase 2 clinical trial evaluating rinvatercept in patients with amyotrophic lateral sclerosis ("ALS") within the Healey ALS MyMatch program ("ALS MyMatch"), led by the Sean M. Healey & AMG Ce

    3/9/26 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference

    LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that it presented additional data from its Phase 1 clinical trial of rinvatercept (KER-065) in healthy volunteers at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. "We are pleased to present additional data that further underscore the wide-ranging therapeutic potential

    3/9/26 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. "The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities," said Jasbir S. Seehra, Ph.D., President and Chief Executive

    3/4/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $328,127 worth of shares (34,925 units at $9.40) (SEC Form 4)

    4 - Keros Therapeutics, Inc. (0001664710) (Issuer)

    4/11/25 9:57:19 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Keros Therapeutics with a new price target

    Wells Fargo initiated coverage of Keros Therapeutics with a rating of Overweight and set a new price target of $26.00

    10/20/25 8:00:48 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by BofA Securities with a new price target

    BofA Securities downgraded Keros Therapeutics from Buy to Neutral and set a new price target of $18.00

    6/10/25 7:53:18 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Keros Therapeutics from Overweight to Neutral

    1/21/25 7:51:46 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    SEC Filings

    View All

    Keros Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Keros Therapeutics, Inc. (0001664710) (Filer)

    3/9/26 8:01:35 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Keros Therapeutics, Inc. (0001664710) (Filer)

    3/4/26 4:08:49 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Keros Therapeutics Inc.

    S-8 - Keros Therapeutics, Inc. (0001664710) (Filer)

    3/4/26 4:08:08 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Leadership Updates

    Live Leadership Updates

    View All

    Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. "The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities," said Jasbir S. Seehra, Ph.D., President and Chief Executive

    3/4/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Charles Newton to its Board of Directors

    LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Charles Newton to its Board of Directors, effective March 9, 2026. "We are pleased to welcome Mr. Newton to Keros' Board of Directors," said Jean-Jacques Bienaimé, Chair of the Board of Directors. "His extensive expertise in healthcare finance and capital markets, coupled with

    2/26/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros Therapeutics Appoints Yung H. Chyung, M.D., as Chief Medical Officer

    LEXINGTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced the appointment of Yung H. Chyung, M.D., as Keros' Chief Medical Officer, effective as of November 1, 2024. "We are thrilled to welcome Yung to Keros and look forward to leveraging his development and TGF-ß superfamily expertise as we continue to advance our clinical programs," said Chair and Chi

    10/16/24 8:00:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Financials

    Live finance-specific insights

    View All

    Keros Therapeutics Reports Third Quarter 2025 Financial Results

    LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended September 30, 2025. "We are excited that our partner Takeda plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept in the first-line setting in myelodysplastic syndromes," said Jasbir S. Seehra, Ph.D., President and Chief Executiv

    11/5/25 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment

    AUSTIN, Texas, Aug. 21, 2025 /PRNewswire/ -- ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1" or "we"), the largest stockholder of Keros Therapeutics (NASDAQ:KROS) ("Keros" or the "Company") with approximately 13.3% of the Company's outstanding shares, today released an open letter to Keros' Board of Directors (the "Board") expressing its disappointment with the Board's refusal to engage with ADAR1 on the Company's strategy, capital allocation priorities and Board refreshment. The full text of the letter is below. Dear Members of the Board: In July, we wrote to the Board privately to propose an in-person meeting to discuss our ideas to maximize stockholder value. We had

    8/21/25 8:30:00 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Keros to Exclusively Prioritize the Clinical Advancement of KER-065

    Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced a strategic realignment designed to reallocate resources towards the development of its key clinical program, KER-065. As part of thi

    8/6/25 4:15:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KROS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/13/24 6:38:35 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    2/9/24 9:16:07 AM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Keros Therapeutics Inc. (Amendment)

    SC 13G/A - Keros Therapeutics, Inc. (0001664710) (Subject)

    1/26/24 5:26:51 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care